SCHEMBL14645934

SCHEMBL14645934

COc1c(C(C)(C)C)cc2c(c1-c1ccccc1)C=C(C)C2[Si](C)(C)C1C(C)=Cc2c(-c3ccc(C(C)(C)C)cc3)cccc21

nearest known ligand 0.30

Predicted protein targets (top 2)

geneUniProtsupporting neighboursconfidence
ALDH1A1 P00352 1/20 0.30
HIF1A Q16665 1/20 0.30

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL15917838 0.97
SCHEMBL15808924 0.93
SCHEMBL15808892 0.92
SCHEMBL15808847 0.91 PDE4A (0.31)
SCHEMBL15931795 0.89 GPR84 (0.30)
SCHEMBL14645915 0.89 PDE4B (0.31)
SCHEMBL20609994 0.88 TDO2 (0.33)
SCHEMBL29906286 0.88 TDO2 (0.33)
SCHEMBL14645919 0.88
SCHEMBL3736095 0.87 PDE4B (0.35) ALDH1A1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 58 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-9630980-B2 Asymmetrical ligands BOREALIS AG (AT) 2017-04-25 US claimed
US-20160024123-A1 Asymmetrical Ligands BOREALIS AG (AT) 2016-01-28 US claimed
EP-2722345-B1 CATALYST FOR THE POLYMERISATION OF OLEFINS BOREALIS AG (AT) 2018-12-05 EP disclosed
EP-2746289-B1 Catalysts BOREALIS AG (AT) 2017-09-27 EP disclosed
EP-2729479-B1 CATALYSTS BOREALIS AG (AT) 2017-09-06 EP disclosed
US-9630980-B2 Asymmetrical ligands BOREALIS AG (AT) 2017-04-25 US disclosed
US-9630980-B2 Asymmetrical ligands BOREALIS AG (AT) 2017-04-25 US disclosed
EP-2722344-B1 POLYMERISATION PROCESS BOREALIS AG (AT) 2017-03-22 EP disclosed
US-9567351-B2 Heterophasic copolymers BOREALIS AG (AT) 2017-02-14 US disclosed
US-9567351-B2 Heterophasic copolymers BOREALIS AG (AT) 2017-02-14 US disclosed
US-9475890-B2 Catalyst BOREALIS AG (AT) 2016-10-25 US disclosed
EP-2729479-A1 CATALYSTS Borealis AG (AT) 2014-05-14 EP disclosed
EP-2729529-A1 HETEROPHASIC COPOLYMERS Borealis AG (AT) 2014-05-14 EP disclosed
WO-2014060540-A1 POLYMERISATION PROCESS AND CATALYST BOREALIS AG (AT) 2014-04-24 WO disclosed
WO-2014060541-A1 POLYMERISATION PROCESS BOREALIS AG (AT) 2014-04-24 WO disclosed
EP-2722345-A1 Catalyst Borealis AG (AT) 2014-04-23 EP disclosed
EP-2722344-A1 Polymerisation process Borealis AG (AT) 2014-04-23 EP disclosed
EP-2722346-A1 Polymerisation process and catalyst Borealis AG (AT) 2014-04-23 EP disclosed
WO-2013007664-A1 HETEROPHASIC COPOLYMERS BOREALIS AG (AT) 2013-01-17 WO disclosed
WO-2013007650-A1 CATALYSTS BOREALIS AG (AT) 2013-01-17 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20160024123-A1 Asymmetrical Ligands CCRL2, AR, CCR2 ALDH1A1 2229/4885HIF1A 2134/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.